tiprankstipranks
Trending News
More News >
Biovica International AB Class B (SE:BIOVIC.B)
:BIOVIC.B
Advertisement

Biovica International AB Class B (BIOVIC.B) AI Stock Analysis

Compare
0 Followers

Top Page

SE:BIOVIC.B

Biovica International AB Class B

(Frankfurt:BIOVIC.B)

Rating:41Neutral
Price Target:
kr0.50
▼(-21.88% Downside)
Biovica International AB Class B faces significant challenges, primarily due to its financial performance, which is marked by consistent losses and negative cash flows. The technical analysis indicates weak market momentum, and the valuation is unattractive due to a negative P/E ratio and lack of dividends. These factors collectively result in a low overall stock score, highlighting the need for strategic improvements to enhance financial health and investor appeal.

Biovica International AB Class B (BIOVIC.B) vs. iShares MSCI Sweden ETF (EWD)

Biovica International AB Class B Business Overview & Revenue Model

Company DescriptionBiovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
How the Company Makes MoneyBiovica International AB generates revenue primarily through the sale of its diagnostic tests, particularly DiviTum. The company collaborates with healthcare providers, research institutions, and pharmaceutical companies to integrate its diagnostic offerings into cancer treatment and clinical trials. Revenue streams include direct sales of test kits, partnerships with laboratories and hospitals for testing services, and licensing agreements. Biovica's growth is also supported by strategic partnerships and collaborations that enhance its market reach and product development capabilities. Additionally, the company's ongoing research and development efforts aim to expand its product portfolio and increase adoption across various markets.

Biovica International AB Class B Financial Statement Overview

Summary
Despite revenue growth, Biovica International AB Class B struggles with consistent losses and negative cash flows. The balance sheet is stable with low leverage, but negative profitability and cash flow issues highlight significant financial challenges.
Income Statement
35
Negative
Biovica International AB Class B shows a substantial revenue growth from SEK 2,045,000 in 2022 to SEK 8,619,000 in 2025, indicating a positive trajectory. However, the company operates with negative EBIT and net income, showing significant losses consistently over the years. Margins remain negative with EBIT and EBITDA margins deteriorating, indicating challenges in profitability despite revenue growth.
Balance Sheet
40
Negative
The company maintains a solid equity base with a high equity ratio, although it has declined as liabilities increased. The debt-to-equity ratio remains low, signaling manageable leverage. However, the negative net income contributes to a negative ROE, reflecting profitability issues. Overall, while the balance sheet is stable, profitability needs improvement.
Cash Flow
30
Negative
Operating cash flows are negative and have worsened over time, reflecting operational challenges. Free cash flow remains negative, with no significant improvements. The company relies on financing activities to sustain operations, which may not be sustainable in the long run without profitability improvements.
BreakdownJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue8.62M7.29M3.38M2.04M2.08M
Gross Profit8.08M6.88M4.62M4.67M5.27M
EBITDA-76.22M-119.51M-105.96M-53.47M-36.56M
Net Income-87.62M-124.82M-110.49M-60.00M-39.48M
Balance Sheet
Total Assets64.95M131.41M172.29M151.63M192.65M
Cash, Cash Equivalents and Short-Term Investments24.41M79.41M114.33M89.79M145.36M
Total Debt4.65M7.83M10.45M13.25M2.42M
Total Liabilities21.74M34.77M33.65M27.54M9.99M
Stockholders Equity43.21M96.64M138.63M124.09M182.66M
Cash Flow
Free Cash Flow-85.65M-114.72M-97.42M-55.52M-37.97M
Operating Cash Flow-85.37M-114.58M-94.64M-52.13M-34.41M
Investing Cash Flow-287.00K-585.00K-2.78M-3.40M-3.56M
Financing Cash Flow30.93M79.50M122.01M-136.00K142.66M

Biovica International AB Class B Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.64
Price Trends
50DMA
0.69
Negative
100DMA
0.72
Negative
200DMA
1.23
Negative
Market Momentum
MACD
-0.01
Negative
RSI
44.62
Neutral
STOCH
33.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOVIC.B, the sentiment is Negative. The current price of 0.64 is below the 20-day moving average (MA) of 0.66, below the 50-day MA of 0.69, and below the 200-day MA of 1.23, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 44.62 is Neutral, neither overbought nor oversold. The STOCH value of 33.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOVIC.B.

Biovica International AB Class B Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
46
Neutral
C$209.14M-0.30-24.12%3.18%19.38%-2.35%
41
Neutral
€143.27M-126.57%18.21%54.65%
€10.93M-18.38%
€10.60M-101.53%
€12.06M-180.76%
€8.83M-104.17%
€11.91M-89.24%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:BIOVIC.B
Biovica International AB Class B
0.64
-1.83
-74.00%
DE:78D
Alzinova AB
0.07
-0.24
-77.42%
DE:8N1
Biosergen AB
0.04
0.00
0.00%
DE:4YD
Nanologica AB
0.10
-0.27
-72.97%
DE:9RP
Lipigon Pharmaceuticals AB
0.01
0.00
0.00%
DE:65G
NextCell Pharma AB
0.09
0.02
28.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025